Jean Weigert, MD, head of breast imaging for the Hospital of Central Connecticut, discusses the benefits of screening women who had normal mammograms but dense breasts.
Jean Weigert, MD, head of breast imaging for the Hospital of Central Connecticut, discusses the benefits of screening women who had normal mammograms but dense breasts.
To make the process easier for the patient and the doctor, patients are given a “reflex to ultrasound if dense” order sheet, Weigert says. Some women do not want to have the ultrasound done, but once women are told they have dense breasts, they are more likely to come back.
Weigert says this has also helped patients be consistent about receiving their yearly mammogram and ultrasound. This process has also helped doctors find cancers when the lesions are smaller, and treatment is less expensive and less stressful for the patient.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.